The FAVOR III trial

The FAVOR III Europe Japan Trial
QFR vs. FFR randomized non-inferiority trial
2000 patients in 35 European and Japanese heart centres

[The FAVOR III trial @FAVORIIITrial]

@Tebaldi_Matteo @BarbaraStahli @Eric_Van_Belle @gret_ziu @m_leistner @HernanDMejiaR @ramirotrillo @Gioquad @enrico_cerrato @AshkanEftekhar1 @ThueOlsen #qfr #coronaryphysiology

[Niels R. Holm @NielsRHolm]

Is QFR non-inferior to FFR?
1200 of 2000 pts included. Hospital Clinico Universitario de Valladolid, Spain, did the milestone case and Sahlgrenska, Sweden leads with 123 cases trailed by 118 in Ferrara, Italy @FAVORIIITrial @ignamatsant @JEscaned @GianlucaCampo78 @SimoneBiscaglia

[The FAVOR III trial @FAVORIIITrial]

Yesterday, prof. @GianlucaCampo78 and his team in Ferrara enrolled patient no 1000 in the @FAVORIIITrial. Ferrara is also the top enrolling center followed by Sahlgenska, Sweden and Clinique Axium, Aix-en-Provence, France. @SimoneBiscaglia @Tebaldi_Matteo @NielsRHolm

[The FAVOR III trial @FAVORIIITrial]

This morning, we reached a major milestone in the FAVOR III trial! Patient number 500 was enrolled by dr. Hernán Mejía-Renteria and his colleagues at Hospital Clinico San Carlos, Madrid. Beyond grateful for the collaboration! #QFR @NielsRHolm @h_evald @B_Krogsgaard @HernanDMejiaR

[The FAVOR III trial @FAVORIIITrial]

First enrolment at Charite - Universitätsmedizin this morning! Congratulations to Prof. Dr. med. Ulf Landmesser and his team. This is great news for the @FAVORIIITrial!

[The FAVOR III trial @FAVORIIITrial]

@FAVORIIITrial News! Two great Italian centers just enrolled their first patient. Congratulations to the teams at University Napoli Federico II and Arcispedale S. Maria Nuova di Reggio Emilia. Good job!
@llddss80 @Iginio51341807 @espogiov #QFR

[The FAVOR III trial @FAVORIIITrial]

It is a great week in the @FAVORIIITrial. Yet another center starting active enrolment! Many thanks to Dr. Karsten Lenk and his team at University Clinic Leipzig for their engagement in this important trial on #QFR vs. FFR.
@NielsRHolm @h_evald @AshkanEftekhar1 @B_Krogsgaard

[The FAVOR III trial @FAVORIIITrial]

Great start to a new week! Dr. Bruno Farah and his team at Clinique Pasteur, Toulouse, just enrolled their first patient in the @FAVORIIITrial. Congratulations! #QFR @NielsRHolm @B_Krogsgaard @WestraJelmer @h_evald @AshkanEftekhar1

[The FAVOR III trial @FAVORIIITrial]

Great news in the @FAVORIIITrial! Yesterday, Dr. Thue Olsen and the FAVOR III team randomized their first patient at Gentofte Hospital, Denmark. Congratulations! #QFR #coronaryphysiology #cardiotwitter @ThueOlsen @NielsRHolm @h_evald

[The FAVOR III trial @FAVORIIITrial]

The second French center has now started active enrolment in the @FAVORIIITrial! Congrats to @juliendjdj and his team at Institut Arnault Tzcank in Nice for enrolling their first two FAVOR III patients this week. Many thanks for your contribution on #QFR vs FFR!

[The FAVOR III trial @FAVORIIITrial]

A true landmark was reached in the @FAVORIIITrial
today! First Spanish patient enrolled by Dr. Hernán Mejía Rentería and the team at Hospital Clínico San Carlos, Madrid in a successful #QFR procedure. Congratulations! @JEscaned @NielsRHolm @B_Krogsgaard @WestraJelmer @h_evald

[The FAVOR III trial @FAVORIIITrial]

Great news from the @FAVORIIITrial! Today, Dr. Liu and the team at Hagaziekenhuis in The Hague became the 7th site to begin enrolment in this exciting trial on #QFR vs FFR #QFRFirst

[The FAVOR III trial @FAVORIIITrial]

What a start by Prof. @GianlucaCampo78, @SimoneBiscaglia and their dream team in Ferrara!! Two first Italian patients enrolled in 24h in the @FAVORIIITrial. #QFR vs FFR in 2000 pts. @FrobertOle @WestraJelmer @AshkanEftekhar1 @DrKoltowski @NielsRHolm @JEscaned

[The FAVOR III trial @FAVORIIITrial]

@FAVORIIITrial news! Dr. Koltowski and colleagues enrolled their first patient at Warsaw University Hospital today. Congratulations! #QFRfirst @DrKoltowski @WestraJelmer @GianlucaCampo78 @JEscaned @h_evald @FrobertOle @AshkanEftekhar1 @TroelsThim @SimoneBiscaglia @NielsRHolm

[The FAVOR III trial @FAVORIIITrial]

Yesterday, the team by Dr. Barbara Stähli, Universitäres Herzzentrum Zürich, Switzerland, randomized their first patient in the 2000 pts @FAVORIIITrial. #QFR #coronaryphysiology #cardiotwitter @FrobertOle @WestraJelmer @DrKoltowski @NielsRHolm @JEscaned @GianlucaCampo78